Last updated: February 22, 2026
What is NDC 78206-0175?
NDC 78206-0175 is a prescription drug marketed by Ciprofa (generic name: ciprofloxacin hydrochloride) as an intravenous (IV) solution. Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic used primarily to treat serious bacterial infections, including intra-abdominal infections, urinary tract infections, and respiratory infections.
Market Dynamics Overview
Therapeutic Area and Demand Drivers
Ciprofloxacin's primary application is in hospitals and acute care settings, with usage rates driven by the prevalence of bacterial infections resistant to other antibiotics. As resistance increases, reliance on ciprofloxacin and other fluoroquinolones remains stable or grows.
Market Size Estimates (2023)
The global antibiotic market was valued at approximately USD 50 billion in 2022, with fluoroquinolones accounting for roughly 10%. The IV segment constitutes about 40% of fluoroquinolone sales, primarily in the US, Europe, and select Asian markets.
Estimated US Market for Ciprofloxacin IV (2023): USD 700 million to USD 900 million.
Growth Rate: 2-4% annually, reflecting steady demand amid rising resistance.
Competitive Landscape
Major competitors include:
- Ciprofloxacin (brand: Cipro, Cipro XR)
- Levofloxacin
- Moxifloxacin
However, the IV formulations face competition from newer antibiotics and combination therapies.
Regulatory Status
Ciprofloxacin IV is FDA-approved with multiple indications. Patent protections expired over a decade ago, with generics available globally, intensifying price competition.
Price Projections
Current Pricing
As of Q1 2023:
- Average wholesale price (AWP): Approximately USD 20–25 per 100 mL vial.
- Estimated acquisition cost for hospitals: USD 15–20 per vial.
- Average selling price (ASP): Largely in the USD 25–35 range, reflecting markup and distribution costs.
Volume Estimates
- Hospital use: ~4–5 million vials annually in the US.
- Pricing pressure: Intense due to generics, with potential for further reductions as biosimilars or alternative antibiotics enter the market.
Price Trend Forecast (2023–2027)
| Year |
Price per Vial (USD) |
Comment |
| 2023 |
25 |
Stabilization amid patent expiry and generic entry |
| 2024 |
23–24 |
Slight decrease as competition intensifies |
| 2025 |
21–22 |
Price erosion continues |
| 2026 |
20–21 |
Market stabilizes; high-volume, low-margin sales |
| 2027 |
19–20 |
Possible further compression due to biosimulation |
Factors Influencing Price Trends
- Generic penetration: Over 90% of prescriptions are now generics.
- Market consolidation: Large hospital groups may negotiate lower prices.
- Regulatory interventions: Potential policies to control antibiotic prices.
- Emergence of alternative therapies: New drugs could reduce ciprofloxacin demand, affecting prices.
Investment and Market Entry Considerations
- Opportunities: Generic manufacturers can compete aggressively on price, likely further reducing margins.
- Risks: Market saturation, political pressure to limit antibiotic prices, and the advent of new antibiotics reduce profitability.
- Strategic move: Focus on geographic regions with less generic penetration, such as emerging markets, where pricing remains higher.
Summary
NDC 78206-0175 (ciprofloxacin IV) operates in a mature, highly competitive market with declining prices driven by generics. The current market value in the US approximates USD 700–900 million, with a modest growth rate. Price projections suggest a gradual decline, with prices dropping below USD 20 per vial within four years under current dynamics.
Key Takeaways
- Ciprofloxacin IV is a mature product with declining prices due to widespread generic competition.
- The US market for ciprofloxacin IV is valued between USD 700 million and USD 900 million.
- Prices are projected to decrease by approximately USD 5–6 per vial over the next five years.
- Market growth remains steady but limited by increasing generic competition and new antibiotic development.
- Markets outside the US, especially in emerging countries, may sustain higher prices.
FAQs
1. Is ciprofloxacin IV likely to remain a profitable market for manufacturers?
Profitability diminishes as generic saturation increases. Producers must seek efficiency and geographic diversification.
2. How does resistance impact ciprofloxacin demand?
Rising resistance may both increase initial demand for effective antibiotics and accelerate the decline as newer therapies replace ciprofloxacin or restrict its use.
3. What are the main competitors to this drug?
Levofloxacin and moxifloxacin are primary oral alternatives; other IV antibiotics include ceftriaxone and meropenem for broad-spectrum needs.
4. Could regulatory policies affect pricing?
Yes, governments may impose price controls or promote antimicrobial stewardship, limiting revenue potential.
5. Is there potential for biosimilar or alternative formulations?
Current biosimilar development is unlikely due to ciprofloxacin being a small-molecule antibiotic; focus remains on generics and combination therapies.
References
[1] IQVIA. (2023). Global Antibiotic Market Report.
[2] U.S. Food and Drug Administration (FDA). (2022). Drug Approvals and Market Status.
[3] MarketsandMarkets. (2022). Fluoroquinolone Antibiotics Market.
